Arcellx (NASDAQ:ACLX - Get Free Report) is expected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.63) per share for the quarter.
Arcellx Price Performance
Shares of Arcellx stock traded down $1.86 during trading hours on Friday, reaching $63.75. The company had a trading volume of 630,308 shares, compared to its average volume of 636,888. The firm has a market cap of $3.45 billion, a PE ratio of -89.79 and a beta of 0.29. Arcellx has a one year low of $47.88 and a one year high of $107.37. The business has a fifty day simple moving average of $70.51 and a 200 day simple moving average of $77.01.
Insider Transactions at Arcellx
In other news, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $91.88, for a total value of $137,820.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Christopher Heery sold 3,301 shares of the business's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $79.55, for a total value of $262,594.55. Following the transaction, the insider now owns 35,517 shares in the company, valued at approximately $2,825,377.35. This represents a 8.50 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,915 shares of company stock worth $1,209,567. Company insiders own 6.24% of the company's stock.
Analyst Ratings Changes
ACLX has been the subject of several research analyst reports. Barclays raised Arcellx to a "strong-buy" rating in a research note on Friday, November 29th. Bank of America lifted their price objective on Arcellx from $84.00 to $100.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. Needham & Company LLC reissued a "buy" rating and set a $105.00 price objective on shares of Arcellx in a research note on Monday, December 9th. Truist Financial lifted their price objective on Arcellx from $87.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, November 12th. Finally, UBS Group lifted their price objective on Arcellx from $106.00 to $114.00 and gave the company a "buy" rating in a research note on Tuesday, December 10th. Thirteen analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $105.93.
Get Our Latest Analysis on ACLX
Arcellx Company Profile
(
Get Free Report)
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
See Also
Before you consider Arcellx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.
While Arcellx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
